Cowen Inc’s Vertex Pharmaceuticals VRTX Stock Holding History

Cowen Inc’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-5,000	Closed	-$372K	–	239
2013 Q4	$372K	Buy	+5,000	New	+$348K	0.06%	180

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cowen Inc's VRTX Position: Q1 2014 in Review

Cowen Inc sold out of Vertex Pharmaceuticals (VRTX) in Q1 2014, closing a stake of 9,500 shares — an estimated $706K sold.

Cowen Inc first reported a position in VRTX in Q2 2013 and held it in 3 quarters. The position peaked at $1.6M in Q2 2013. 395 funds tracked by Wall St. Rank hold VRTX as of Q1 2014.

Cowen Inc reported no remaining Vertex Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
Cowen Inc sold 9,500 Vertex Pharmaceuticals shares in Q1 2014, an estimated $706K.
Cowen Inc first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 3 quarters.
Cowen Inc's Vertex Pharmaceuticals position peaked at $1.6M in Q2 2013.
395 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2014.

Based on Cowen Inc's 13F filing for Q1 2014, filed 16 May 2014.